RYTM to report Q2 results with a consensus EPS loss of $0.83 and revenue of $67.66M before market open.
Rhythm Pharmaceuticals will unveil its Q2 2026 financial results on August 4, prior to the market opening. Analysts expect the company to post a loss of $0.83 per share on revenue of $67.66M.
Over the past year, RYTM has consistently surpassed earnings per share estimates, though revenue performance has varied. The upcoming report will provide insight into whether the company can maintain its trend of beating expectations amid ongoing operational challenges.
No immediate market reaction details are available ahead of the release.